Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

Conditions:   Breast Cancer;   Breast Neoplasms;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Drug: Parsaclisib Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials